Cindy Kin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cindy Kin has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Andrew Shelton
Department of Surgery, Stanford University School of Medicine, Stanford, California
4 shared publicationsLindsay A. Sceats
Department of Surgery, Stanford University School of Medicine, Stanford, California
4 shared publications- Lindsay Anne Sceats
Department of Surgery, Stanford University, Stanford, California, USA
4 shared publications Andrew A. Shelton
Department of Surgery, Section of Colon and Rectal Surgery, Stanford University School of Medicine, Stanford, California
3 shared publicationsElizabeth Shelton
Department of Surgery, Stanford University School of Medicine, Stanford, USA
3 shared publicationsSerena Bidwell
University of Michigan Medical School, Ann Arbor
3 shared publications
Latest Publications
- 5 August 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 69 (11) , 2673-2682
Trends in the Utilization of 2-Stage Versus 3-Stage IPAA Among Privately Insured Patients With Ulcerative Colitis in the United States (2007–2023)
BACKGROUND: IPAA can be performed via 2- and 3-stage techniques, with similar short- and long-term clinical outcomes. Two-stage IPAA became the predominant approach in the 2000s; whether this trend has continued remains unknown. OBJECTIVE: To compare trends in the utilization of 3-stage, traditional 2-stage, and modified 2-stage IPAA for ulcerative colitis as well as markers of disease severity over time. DESIGN: Retrospective cohort. SETTINGS: Privately insured patients from an administrative database. PATIENTS: Nonelderly adults with a diagnosis of ulcerative colitis who underwent IPAA between 2007 and 2023 and remained enrolled in their insurance plan for ≥6 months after surgery. MAIN OUTCOME MEASURES: Proportion of patients undergoing 3-stage, traditional 2-stage, and modified 2-stage IPAA; annualized change in disease severity at the time of IPAA creation. RESULTS: Four thousand thirty-nine patients underwent IPAA during the study period (2179 traditional 2-stage, 1107 3-stage, and 753 modified 2-stage). The proportion of patients undergoing a traditional 2-stage IPAA decreased steadily (1.3% points per year [95% CI, −1.7 to −0.9]) with a commensurate rise in both 3-stage (0.3% points per year [95% CI, −0.02 to 0.7]) and modified 2-stage operations (0.9% points per year [95% CI, 0.6–1.2]). Patients undergoing 3-stage or modified 2-stage IPAA had a more rapid increase in exposure to advanced therapies in the year before surgery (+2.9 vs +2.0% points). LIMITATIONS: Potential misclassification, generalizability. CONCLUSIONS: More patients are undergoing 3-stage and modified 2-stage operations than traditional 2-stage IPAA. This shift parallels an increase in multiple markers of disease severity at IPAA creation, especially exposure to advanced therapies. See Video Abstract . TENDENCIAS EN LA UTILIZACIÓN DE LA ANASTOMOSIS ILEOANAL CON RESERVORIO EN DOS ETAPAS FRENTE A LA DE TRES ETAPAS ENTRE PACIENTES CON COLITIS ULCEROSA ASEGURADOS DE FORMA PRIVADA EN LOS EE. UU., 2007 A 2023: ANTECEDENTES: La anastomosis ileoanal con reservorio puede realizarse mediante técnicas de dos y tres etapas, con resultados clínicos similares a corto y largo plazo. La anastomosis ileoanal con reservorio en dos etapas se convirtió en el enfoque predominante en la década de 2000; se desconoce si esta tendencia se ha mantenido. OBJETIVO: Comparar las tendencias en la utilización de la anastomosis ileoanal con reservorio en tres etapas, la técnica tradicional de dos etapas y la técnica modificada de dos etapas para la colitis ulcerosa, así como los marcadores de gravedad de la enfermedad a lo largo del tiempo. DISEÑO: Cohorte retrospectiva. ÁMBITO: Pacientes con seguro médico privado procedentes de una base de datos administrativa. PACIENTES: Adultos no ancianos con diagnóstico de colitis ulcerosa que se sometieron a anastomosis ileoanal con reservorio entre 2007 y 2023 y que mantuvieron su cobertura de seguro médico durante al menos 6 meses después de la cirugía. PRINCIPALES MEDIDAS DE RESULTADO: Proporción de pacientes sometidos a anastomosis ileoanal con reservorio en 3 etapas, tradicional en 2 etapas y modificada en 2 etapas; cambio anualizado en la gravedad de la enfermedad al momento de la creación de la anastomosis ileoanal con reservorio. RESULTADOS: Cuatro mil treinta y nueve pacientes se sometieron a anastomosis ileoanal con reservorio durante el período de estudio (2179 tradicionales en 2 etapas; 1107 en 3 etapas; y 753 modificadas en 2 etapas). La proporción de pacientes sometidos a IPAA tradicional en dos etapas disminuyó progresivamente (1,3 puntos porcentuales por año [IC del 95%: -1,7 a -0,9]), con un aumento proporcional tanto en las operaciones en tres etapas (0,3 puntos porcentuales por año [IC del 95%: -0,02 a 0,7]) como en las modificadas en dos etapas (0,9 puntos porcentuales por año [IC del 95%: 0,6 a 1,2]). Los pacientes sometidos a IPAA en tres etapas o modificada en dos etapas presentaron un aumento más rápido en la exposición a terapias avanzadas durante el año previo a la cirugía (+2,9 frente a +2,0 puntos porcentuales). Limitaciones: posible clasificación errónea, generalización. CONCLUSIONES: Un mayor número de pacientes se somete a operaciones en tres etapas y modificadas en dos etapas que a la anastomosis ileoanal tradicional en dos etapas. Este cambio coincide con un aumento en múltiples marcadores de gravedad de la enfermedad al momento de la creación de la IPAA, especialmente la exposición a terapias avanzadas. ( AI-generated translated )
- 5 August 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 69 (11) , 2673-2682
Trends in the Utilization of 2-Stage Versus 3-Stage IPAA Among Privately Insured Patients With Ulcerative Colitis in the United States (2007–2023)
BACKGROUND: IPAA can be performed via 2- and 3-stage techniques, with similar short- and long-term clinical outcomes. Two-stage IPAA became the predominant approach in the 2000s; whether this trend has continued remains unknown. OBJECTIVE: To compare trends in the utilization of 3-stage, traditional 2-stage, and modified 2-stage IPAA for ulcerative colitis as well as markers of disease severity over time. DESIGN: Retrospective cohort. SETTINGS: Privately insured patients from an administrative database. PATIENTS: Nonelderly adults with a diagnosis of ulcerative colitis who underwent IPAA between 2007 and 2023 and remained enrolled in their insurance plan for ≥6 months after surgery. MAIN OUTCOME MEASURES: Proportion of patients undergoing 3-stage, traditional 2-stage, and modified 2-stage IPAA; annualized change in disease severity at the time of IPAA creation. RESULTS: Four thousand thirty-nine patients underwent IPAA during the study period (2179 traditional 2-stage, 1107 3-stage, and 753 modified 2-stage). The proportion of patients undergoing a traditional 2-stage IPAA decreased steadily (1.3% points per year [95% CI, −1.7 to −0.9]) with a commensurate rise in both 3-stage (0.3% points per year [95% CI, −0.02 to 0.7]) and modified 2-stage operations (0.9% points per year [95% CI, 0.6–1.2]). Patients undergoing 3-stage or modified 2-stage IPAA had a more rapid increase in exposure to advanced therapies in the year before surgery (+2.9 vs +2.0% points). LIMITATIONS: Potential misclassification, generalizability. CONCLUSIONS: More patients are undergoing 3-stage and modified 2-stage operations than traditional 2-stage IPAA. This shift parallels an increase in multiple markers of disease severity at IPAA creation, especially exposure to advanced therapies. See Video Abstract . TENDENCIAS EN LA UTILIZACIÓN DE LA ANASTOMOSIS ILEOANAL CON RESERVORIO EN DOS ETAPAS FRENTE A LA DE TRES ETAPAS ENTRE PACIENTES CON COLITIS ULCEROSA ASEGURADOS DE FORMA PRIVADA EN LOS EE. UU., 2007 A 2023: ANTECEDENTES: La anastomosis ileoanal con reservorio puede realizarse mediante técnicas de dos y tres etapas, con resultados clínicos similares a corto y largo plazo. La anastomosis ileoanal con reservorio en dos etapas se convirtió en el enfoque predominante en la década de 2000; se desconoce si esta tendencia se ha mantenido. OBJETIVO: Comparar las tendencias en la utilización de la anastomosis ileoanal con reservorio en tres etapas, la técnica tradicional de dos etapas y la técnica modificada de dos etapas para la colitis ulcerosa, así como los marcadores de gravedad de la enfermedad a lo largo del tiempo. DISEÑO: Cohorte retrospectiva. ÁMBITO: Pacientes con seguro médico privado procedentes de una base de datos administrativa. PACIENTES: Adultos no ancianos con diagnóstico de colitis ulcerosa que se sometieron a anastomosis ileoanal con reservorio entre 2007 y 2023 y que mantuvieron su cobertura de seguro médico durante al menos 6 meses después de la cirugía. PRINCIPALES MEDIDAS DE RESULTADO: Proporción de pacientes sometidos a anastomosis ileoanal con reservorio en 3 etapas, tradicional en 2 etapas y modificada en 2 etapas; cambio anualizado en la gravedad de la enfermedad al momento de la creación de la anastomosis ileoanal con reservorio. RESULTADOS: Cuatro mil treinta y nueve pacientes se sometieron a anastomosis ileoanal con reservorio durante el período de estudio (2179 tradicionales en 2 etapas; 1107 en 3 etapas; y 753 modificadas en 2 etapas). La proporción de pacientes sometidos a IPAA tradicional en dos etapas disminuyó progresivamente (1,3 puntos porcentuales por año [IC del 95%: -1,7 a -0,9]), con un aumento proporcional tanto en las operaciones en tres etapas (0,3 puntos porcentuales por año [IC del 95%: -0,02 a 0,7]) como en las modificadas en dos etapas (0,9 puntos porcentuales por año [IC del 95%: 0,6 a 1,2]). Los pacientes sometidos a IPAA en tres etapas o modificada en dos etapas presentaron un aumento más rápido en la exposición a terapias avanzadas durante el año previo a la cirugía (+2,9 frente a +2,0 puntos porcentuales). Limitaciones: posible clasificación errónea, generalización. CONCLUSIONES: Un mayor número de pacientes se somete a operaciones en tres etapas y modificadas en dos etapas que a la anastomosis ileoanal tradicional en dos etapas. Este cambio coincide con un aumento en múltiples marcadores de gravedad de la enfermedad al momento de la creación de la IPAA, especialmente la exposición a terapias avanzadas. ( AI-generated translated )
- 2 July 2025
- Published by BMJ in Evidence-Based Nursing
- Vol. 29 (3) , 162
Improving colorectal cancer screening in patients with comorbidities requires personalised patient education: an invited commentary
- 2 July 2025
- Published by BMJ in Evidence-Based Nursing
- Vol. 29 (3) , 162
Improving colorectal cancer screening in patients with comorbidities requires personalised patient education: an invited commentary
- 13 June 2025
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (9) , 1062-1073
Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study
BACKGROUND: The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined. OBJECTIVE: To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort. DESIGN: Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023. SETTING: Seventeen medical centers. PATIENTS: Patients with IBD undergoing colectomy and/or proctectomy were included. INTERVENTIONS: Chemoprophylaxis. MAIN OUTCOME MEASURES: Thirty-day venous thromboembolism (clot) rates. RESULTS: During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome (p = 0.0005) and extended resections (p < 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively (p < 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge (p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively. LIMITATIONS: The limitations to this study were generalizability and selection bias. CONCLUSIONS: After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract. PATRONES DE PRÁCTICA, RESULTADOS Y ESTRATIFICACIÓN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGÍA POR ENFERMEDAD INFLAMATORIA INTESTINAL: ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRÚRGICA SOBRE EII: ANTECEDENTES: No se ha definido la estrategia óptima de quimioprofilaxis de la tromboembolia venosa tras la cirugía por enfermedad inflamatoria intestinal. OBJETIVO: Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirugía por enfermedad inflamatoria intestinal en una cohorte retrospectiva. DISEÑO: Entre julio de 2020 y octubre de 2023, la Colaboración sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quirúrgica. ENTORNO: Diecisiete centros médicos. PACIENTES: Pacientes con enfermedad inflamatoria intestinal sometidos a colectomía y/o proctectomía. INTERVENCIONES: Quimioprofilaxis. PRINCIPALES MEDIDAS DE RESULTADO: Tasas de tromboembolia venosa (coágulos) a 30 días. RESULTADOS: Durante tres años, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un coágulo en un plazo de 30 días: el 50 % antes y después del alta, respectivamente. Los coágulos se diagnosticaron una mediana de 9 días después de la operación. Los coágulos más frecuentes fueron portomesentéricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de coágulos difirieron según la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utilizó una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de coágulos difirieron según la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorrágicas. El análisis multivariable reveló que el síndrome de respuesta inflamatoria sistémica preoperatoria (p = 0.0005) y las resecciones extendidas (p < 0.0001) eran factores de riesgo independientes para los coágulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de coágulos del 1.2 %, 4.0 % y 13.5 %, respectivamente (p < 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoció de forma independiente con un menor riesgo de coágulos antes y después del alta (p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de coágulos del 2.5 %, el número estimado de pacientes que debían recibir tratamiento con enoxaparina durante la hospitalización y después del alta fue de 54 y 55, respectivamente. LIMITACIONES: Generalización; sesgo de selección. CONCLUSIONES: Tras la cirugía por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoció con una disminución del riesgo de coágulos antes y después del alta. Los pacientes con mayor riesgo pueden beneficiarse más de una quimioprofilaxis prolongada. (Traducción—Dr. Jorge Silva Velazco)
- 13 June 2025
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (9) , 1062-1073
Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study
BACKGROUND: The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined. OBJECTIVE: To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort. DESIGN: Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023. SETTING: Seventeen medical centers. PATIENTS: Patients with IBD undergoing colectomy and/or proctectomy were included. INTERVENTIONS: Chemoprophylaxis. MAIN OUTCOME MEASURES: Thirty-day venous thromboembolism (clot) rates. RESULTS: During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome (p = 0.0005) and extended resections (p < 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively (p < 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge (p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively. LIMITATIONS: The limitations to this study were generalizability and selection bias. CONCLUSIONS: After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract. PATRONES DE PRÁCTICA, RESULTADOS Y ESTRATIFICACIÓN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGÍA POR ENFERMEDAD INFLAMATORIA INTESTINAL: ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRÚRGICA SOBRE EII: ANTECEDENTES: No se ha definido la estrategia óptima de quimioprofilaxis de la tromboembolia venosa tras la cirugía por enfermedad inflamatoria intestinal. OBJETIVO: Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirugía por enfermedad inflamatoria intestinal en una cohorte retrospectiva. DISEÑO: Entre julio de 2020 y octubre de 2023, la Colaboración sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quirúrgica. ENTORNO: Diecisiete centros médicos. PACIENTES: Pacientes con enfermedad inflamatoria intestinal sometidos a colectomía y/o proctectomía. INTERVENCIONES: Quimioprofilaxis. PRINCIPALES MEDIDAS DE RESULTADO: Tasas de tromboembolia venosa (coágulos) a 30 días. RESULTADOS: Durante tres años, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un coágulo en un plazo de 30 días: el 50 % antes y después del alta, respectivamente. Los coágulos se diagnosticaron una mediana de 9 días después de la operación. Los coágulos más frecuentes fueron portomesentéricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de coágulos difirieron según la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utilizó una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de coágulos difirieron según la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorrágicas. El análisis multivariable reveló que el síndrome de respuesta inflamatoria sistémica preoperatoria (p = 0.0005) y las resecciones extendidas (p < 0.0001) eran factores de riesgo independientes para los coágulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de coágulos del 1.2 %, 4.0 % y 13.5 %, respectivamente (p < 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoció de forma independiente con un menor riesgo de coágulos antes y después del alta (p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de coágulos del 2.5 %, el número estimado de pacientes que debían recibir tratamiento con enoxaparina durante la hospitalización y después del alta fue de 54 y 55, respectivamente. LIMITACIONES: Generalización; sesgo de selección. CONCLUSIONES: Tras la cirugía por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoció con una disminución del riesgo de coágulos antes y después del alta. Los pacientes con mayor riesgo pueden beneficiarse más de una quimioprofilaxis prolongada. (Traducción—Dr. Jorge Silva Velazco)
- 31 December 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 241, 116175
Physiologic readiness and subjective workload of performing operations: A prospective observational study of attending and trainee surgeons
- 31 December 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 241, 116175
Physiologic readiness and subjective workload of performing operations: A prospective observational study of attending and trainee surgeons
- 6 November 2023
- Published by Wiley in World Journal of Surgery
- Vol. 47 (12) , 3138-3139
Remote Telemonitoring with a Human Touch: a Promising Addition to Post-discharge Care for Surgical Patients
- 6 November 2023
- Published by Wiley in World Journal of Surgery
- Vol. 47 (12) , 3138-3139
Remote Telemonitoring with a Human Touch: a Promising Addition to Post-discharge Care for Surgical Patients
- Open Access
- 1 January 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (1) , 100-102
Association of an Online Home-Based Prehabilitation Program With Outcomes After Colorectal Surgery
Prehabilitation programs in colorectal surgery have been studied in multiple centers and have shown promising results.1 However, most studies have tested in-person, resource-intensive programs, which have limited scalability and generalizability for most medical centers and surgeons’ practices. We evaluated the association of an online home-based prehabilitation program with surgical outcomes of patients undergoing colorectal surgery.
- 1 January 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (1) , 100-102
Open AccessAssociation of an Online Home-Based Prehabilitation Program With Outcomes After Colorectal Surgery
Prehabilitation programs in colorectal surgery have been studied in multiple centers and have shown promising results.1 However, most studies have tested in-person, resource-intensive programs, which have limited scalability and generalizability for most medical centers and surgeons’ practices. We evaluated the association of an online home-based prehabilitation program with surgical outcomes of patients undergoing colorectal surgery.
- 22 November 2022
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 54 (3) , 703-711
Is It Really Gone? Assessing Response to Neoadjuvant Therapy in Rectal Cancer
Purpose Non-operative management of rectal cancer is a feasible and appealing treatment option for patients who develop a complete response after neoadjuvant therapy. However, identifying patients who are complete responders is often a challenge. This review aims to present and discuss current evidence and recommendations regarding the assessment of treatment response in rectal cancer. Methods A review of the current literature on rectal cancer restaging was performed. Studies included in this review explored the optimal interval between the end of neoadjuvant therapy and restaging, as well as modalities of assessment and their diagnostic performance. Results The current standard for restaging rectal cancer is a multimodal assessment with the digital rectal examination, endoscopy, and T2-weighted MRI with diffusion-weighted imaging. Other diagnostic procedures under investigation are PET/MRI, radiomics, confocal laser endomicroscopy, artificial intelligence-assisted endoscopy, cell-free DNA, and prediction models incorporating one or more of the above-mentioned exams. Conclusion Non-operative management of rectal cancer requires a multidisciplinary approach. Understanding of the robustness and limitations of each exam is critical to inform patient selection for that treatment strategy.
- 22 November 2022
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 54 (3) , 703-711
Is It Really Gone? Assessing Response to Neoadjuvant Therapy in Rectal Cancer
Purpose Non-operative management of rectal cancer is a feasible and appealing treatment option for patients who develop a complete response after neoadjuvant therapy. However, identifying patients who are complete responders is often a challenge. This review aims to present and discuss current evidence and recommendations regarding the assessment of treatment response in rectal cancer. Methods A review of the current literature on rectal cancer restaging was performed. Studies included in this review explored the optimal interval between the end of neoadjuvant therapy and restaging, as well as modalities of assessment and their diagnostic performance. Results The current standard for restaging rectal cancer is a multimodal assessment with the digital rectal examination, endoscopy, and T2-weighted MRI with diffusion-weighted imaging. Other diagnostic procedures under investigation are PET/MRI, radiomics, confocal laser endomicroscopy, artificial intelligence-assisted endoscopy, cell-free DNA, and prediction models incorporating one or more of the above-mentioned exams. Conclusion Non-operative management of rectal cancer requires a multidisciplinary approach. Understanding of the robustness and limitations of each exam is critical to inform patient selection for that treatment strategy.
- 1 September 2022
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 27 (3) , 565-567
Adherence to a Home-Based Prehabilitation Program for Patients Undergoing Colorectal Surgery
- 1 September 2022
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 27 (3) , 565-567
Adherence to a Home-Based Prehabilitation Program for Patients Undergoing Colorectal Surgery
- 8 April 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46 (7) , 1667-1668
Mitigating Bias in Postoperative Pain Management: a Critical Piece of the Opioid Puzzle
- 8 April 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46 (7) , 1667-1668
Mitigating Bias in Postoperative Pain Management: a Critical Piece of the Opioid Puzzle